公开(公告)号：US12090127B2

公开(公告)日：2024-09-17

申请号：US17584031

申请日：2022-01-25

Applicant: The Trustees of Indiana University

Inventor： Jingwu Xie

IPC: A61P11/00 ,  A61K31/166 ,  A61K33/36 ,  A61P9/10 ,  A61B5/318 ,  A61B5/329 ,  A61B8/08 ,  A61K31/395 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4402 ,  A61K31/444 ,  A61K31/454 ,  A61K31/496 ,  A61K31/502 ,  A61K31/505 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/58 ,  A61K39/395 ,  A61P1/16 ,  C07K16/18

CPC classification number: A61K31/166 ,  A61K33/36 ,  A61P9/10 ,  A61P11/00 ,  A61B5/318 ,  A61B5/329 ,  A61B8/0883 ,  A61K31/395 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4402 ,  A61K31/444 ,  A61K31/454 ,  A61K31/496 ,  A61K31/502 ,  A61K31/505 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/58 ,  A61K39/3955 ,  A61P1/16 ,  C07K16/18

Abstract: Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.

公开(公告)号：US20240299402A1

公开(公告)日：2024-09-12

申请号：US18436306

申请日：2024-02-08

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Joseph VACCA

IPC: A61K31/5377 ,  A61K31/4412 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/513 ,  A61P1/16 ,  C07D213/82 ,  C07D239/36 ,  C07D239/56 ,  C07D295/135 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D498/04 ,  C07D513/04

CPC classification number: A61K31/5377 ,  A61K31/4412 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/513 ,  A61P1/16 ,  C07D213/82 ,  C07D239/36 ,  C07D239/56 ,  C07D295/135 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D498/04 ,  C07D513/04

Abstract: The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

公开(公告)号：US12084504B2

公开(公告)日：2024-09-10

申请号：US17397510

申请日：2021-08-09

Applicant: AGOMAB THERAPEUTICS

Inventor： Paolo Michieli

IPC: C07K16/28 ,  A61K39/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P13/12 ,  A61P29/00

CPC classification number: C07K16/2863 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P13/12 ,  A61P29/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.

公开(公告)号：US20240285808A1

公开(公告)日：2024-08-29

申请号：US18290135

申请日：2022-05-13

Applicant: The General Hospital Corporation

Inventor： Peter Caravan ,  Yingying Ning ,  Hua MA ,  Sergey Shuvaev ,  Eman Akam

IPC: A61K49/10 ,  A61P1/16 ,  C07D255/02 ,  C07D257/02 ,  C07D403/12 ,  C07D417/12 ,  C07D471/08 ,  C07F1/08 ,  C07F3/06 ,  C07F5/00 ,  C07F13/00

CPC classification number: A61K49/106 ,  A61K49/108 ,  A61P1/16 ,  C07D255/02 ,  C07D257/02 ,  C07D403/12 ,  C07D417/12 ,  C07D471/08 ,  C07F1/08 ,  C07F3/06 ,  C07F5/003 ,  C07F13/005

Abstract: Disclosed herein are methods of molecular magnetic resonance (MR) imaging and positron emission tomography using extracellular probes that target extracellular allysine aldehyde and act as a noninvasive biomarker of fibrogenesis with high sensitivity and specificity in detecting fibrogenesis, for example, in rodent models and human fibrotic tissues.

公开(公告)号：US12071431B2

公开(公告)日：2024-08-27

申请号：US17293877

申请日：2019-11-14

Applicant: ALLINKY BIOPHARMA

Inventor： Miguel Vega ,  Esther Carrasco ,  Patricia Gómez ,  Pedro Campos ,  Juan Gómez-Reino ,  Juan Jesús Pérez ,  Ángel Messeguer

IPC: C07D405/14 ,  A61P1/16 ,  C07D213/70 ,  C07D401/04 ,  C07D401/14

CPC classification number: C07D405/14 ,  A61P1/16 ,  C07D213/70 ,  C07D401/04 ,  C07D401/14

Abstract: The present invention relates to a novel class of pyridine-sulfonamide compounds and to compositions comprising the same. The compounds and compositions are useful as medicaments in the treatment of diseases responsive to inhibition of IL-1β, such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).

公开(公告)号：US20240277745A1

公开(公告)日：2024-08-22

申请号：US18564115

申请日：2022-05-25

Applicant: KOWA COMPANY, LTD

Inventor： Noboru KANETA ,  Ryu OSHIMA ,  Shona Sanchita PENDSE ,  Ryohei TANIGAWA

IPC: A61K31/7048 ,  A61K31/423 ,  A61P1/16

CPC classification number: A61K31/7048 ,  A61K31/423 ,  A61P1/16

Abstract: Pemafibrate, tofogliflozin, or combinations thereof for use in treating human patients with liver diseases, particularly NASH patients suffering from liver stiffness or liver fibrosis, NASH patients with lobular inflammation, NASH patients with elevated LDL-C, and NASH patients with healthy triglyceride levels.

公开(公告)号：US12053443B2

公开(公告)日：2024-08-06

申请号：US17232527

申请日：2021-04-16

Applicant: HEPANOVA, INC.

Inventor： Ke Li ,  Belle Xiaohong Wang ,  Yongmei Li ,  Qiong Li

IPC: A61K31/18 ,  A61K31/17 ,  A61P1/16

CPC classification number: A61K31/18 ,  A61K31/17 ,  A61P1/16

Abstract: A method for the treatment and/or reduction of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is disclosed. The method uses active amino-aryl-benzamide compounds and methods for the preparation thereof.

公开(公告)号：US20240254239A1

公开(公告)日：2024-08-01

申请号：US18574243

申请日：2022-06-30

Applicant: LAEKNA THERAPEUTICS SHANGHAI CO., LTD.

Inventor： Chris Xiangyang LU ,  Xiang-Ju Justin GU ,  Minhua ZHANG ,  Ruipeng ZHANG

IPC: C07K16/28 ,  A61K39/00 ,  A61P1/16 ,  C07K16/22 ,  C07K16/40

CPC classification number: C07K16/2851 ,  A61P1/16 ,  C07K16/22 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732

Abstract: A binding molecule comprising a binding domain that binds to an antigen expressed on an activated hepatic stellate cells (HSC), and a functional domain that is capable of enhancing an antibody effector function such as antibody-dependent cell-mediated cytotoxicity (ADCC) toward activated HSCs. Uses of such binding molecule are also provided herein.

公开(公告)号：US20240245789A1

公开(公告)日：2024-07-25

申请号：US18559579

申请日：2022-05-10

Applicant: Arbormentis LLC

Inventor： Sara De Martin ,  Andrea Mattarei ,  Marco Banzato ,  Daniela Gabbia ,  Gianfranco Pasut ,  Paolo L. Manfredi

IPC: A61K47/60 ,  A61P1/16

CPC classification number: A61K47/60 ,  A61P1/16

Abstract: Psychedelic drug (PD) polymer conjugates having a general structure PD-(X-Poly-T)n, wherein PD is a CNS active psychedelic drug targeting serotonergic receptors, with possible affinity also for other receptors. (X-Poly-T) is, independently for each occurrence, hydrogen or the moieties are, independently: X is a stable (enzymatically and/or hydrolytically under physiological conditions) linker comprising a covalent bond or a chain of atoms that covalently attaches a small molecule 5-HT receptors agonist drug moiety to the Poly derivative. Poly is a covalently bonded chain of repeating monomer units that form a polymer or an oligomer backbone of synthetic or natural origin. T is terminal group of Poly and is represented by any suitable chemical group which, depending upon preference, is unreactive or reactive with other chemical moieties, or has a targeting property. N is an integer comprised between 1 and 6.

公开(公告)号：US20240226173A1

公开(公告)日：2024-07-11

申请号：US18560304

申请日：2022-05-12

Applicant: PrimeGen US, Inc.

Inventor： Joel Marh

IPC: A61K35/28 ,  A61P1/16 ,  C12N5/0775

CPC classification number: A61K35/28 ,  A61P1/16 ,  C12N5/0665

Abstract: Provided are methods of treatment comprising administering to a subject, in need thereof, a therapeutically effective amount of activated stem cells to the affected tissue or organ. The methods described herein are treatment modalities employing mesenchymal stem cells (MSC) in the treatment of mammals, as well as MSC purification and formulation methods including the “activation” or “preconditioning” of stem cells.